<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00165217</url>
  </required_header>
  <id_info>
    <org_study_id>01-141</org_study_id>
    <nct_id>NCT00165217</nct_id>
  </id_info>
  <brief_title>Capecitabine and Thalidomide in Previously Treated Metastatic Colorectal Carcinoma</brief_title>
  <official_title>A Phase II Trial of Capecitabine and Thalidomide in Previously Treated Metastatic Colorectal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to collect information about the antitumor activity and the&#xD;
      safety of capecitabine and thalidomide in patients with colorectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Patients will take capecitabine orally twice a day for two weeks followed by a one week&#xD;
           break period. These three week cycles will continue as long as the patient continues to&#xD;
           benefit from the the therapy and does not experience intolerable side effects.&#xD;
&#xD;
        -  Thalidomide will be taken orally once daily in the evening. Each week teh daily dose of&#xD;
           the medication will be increased by 100mg as long as the patient is not experiencing any&#xD;
           moderate to severe side effects. The dose will be increased in this manner until the&#xD;
           daily dose is 600mg. If side effects do develop, the dose will either be held constant&#xD;
           or decreased until the side effects resolve. If the side effects do not resolve,&#xD;
           treatment will be stopped.&#xD;
&#xD;
        -  Before starting treatment and periodically throughout the study, a physical exam,&#xD;
           routine blood tests, scans and x-rays will be done to monitor the body's response to the&#xD;
           treatment.&#xD;
&#xD;
        -  For women patients, pregnancy tests will be performed every 3 weeks while on therapy.&#xD;
&#xD;
        -  Scans and x-rays will be performed every 9 weeks (after every 3 cycles of treatment) to&#xD;
           follow the effects of the study drugs on the tumor.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2001</start_date>
  <completion_date type="Actual">December 2005</completion_date>
  <primary_completion_date type="Actual">December 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the anti-tumor activity of capecitabine and thalidomide when administered to patients with previously treated metastatic colorectal cancer.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety of capecitabine and thalidomide in this patient population.</measure>
  </secondary_outcome>
  <enrollment>37</enrollment>
  <condition>Colorectal Adenocarcinoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thalidomide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologic proof of colorectal adenocarcinoma with radiological or cytological&#xD;
             evidence of stage IV (metastatic) disease&#xD;
&#xD;
          -  Measurable tumor&#xD;
&#xD;
          -  Serum creatinine &lt; 1.5 mg/dl&#xD;
&#xD;
          -  Total bilirubin &lt; 2.0 mg/dl&#xD;
&#xD;
          -  AST &lt; 5 x ULN&#xD;
&#xD;
          -  ANC &gt; 1,500/mm3&#xD;
&#xD;
          -  Platelets &gt; 100,000/mm3&#xD;
&#xD;
          -  Hemoglobin &gt; 9.0 gm/dl&#xD;
&#xD;
          -  Must have received at least one prior chemotherapy regimen for metastatic colorectal&#xD;
             cancer. At least 3 weeks must have passed since the last chemotherapy treatment&#xD;
&#xD;
          -  18 years of age or older&#xD;
&#xD;
          -  ECOG performance status of less than or equal to 2&#xD;
&#xD;
          -  Life expectancy of greater than 12 weeks&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with mitomycin C or nitrosourea compounds&#xD;
&#xD;
          -  Prior treatment with capecitabine or thalidomide&#xD;
&#xD;
          -  Clinically apparent central nervous system metastases or carcinomatous meningitis&#xD;
&#xD;
          -  Peripheral neuropathy of grade 2 or greater severity&#xD;
&#xD;
          -  Myocardial infarction in the past 6 months&#xD;
&#xD;
          -  Major surgery in the past 2 weeks&#xD;
&#xD;
          -  Uncontrolled serious medical or psychiatric illness&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Concurrent malignancy of any site, except limited basal cell carcinoma or squamous&#xD;
             cell carcinoma of the skin or carcinoma in situ of the cervix.&#xD;
&#xD;
          -  Known allergy to 5-FU&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles S. Fuchs, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2007</verification_date>
  <study_first_submitted>September 9, 2005</study_first_submitted>
  <study_first_submitted_qc>September 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2005</study_first_posted>
  <last_update_submitted>December 20, 2007</last_update_submitted>
  <last_update_submitted_qc>December 20, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 21, 2007</last_update_posted>
  <keyword>capecitabine</keyword>
  <keyword>thalidomide</keyword>
  <keyword>colorectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

